This paper compared genotyping results by next-generation sequencing (NGS) with those by conventional methods in formalin-fixed paraffin embedded (FFPE) lung adenocarcinoma specimens.
A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma.
Purpose
Conclusion
NGS detected all mutations identified by conventional methods as well as some additional ones including therapeutically-actionable mutations in some specimens.
Studies (1)
Purpose
This study compared genotyping results by next-generation sequencing with those by conventional methods in 119 FFPE lung adenocarcinoma specimens. After xylene deparaffinization, DNA was extracted using the QIAamp DNA FFPE tissue kit. A panel of 145 genes was sequenced using an Ion Proton Sequencer. The results were compared with those obtained previously using amplification refractory mutation system (ARMS)-PCR, fluorescent in situ hybridization (FISH), or Sanger Sequencing.
Summary of Findings
NGS detected all mutations identified by ARMS-PCR, FISH, or Sanger Sequencing in 61 specimens, including those in specimens containing only 10-15% tumor cells. However, additional mutations were identified by NGS in some specimens that were not identified by ARMS-PCR or FISH. Further, using an additional 58 specimens, NGS identified 1.4 times as many actionable mutations as ARMS-PCR or FISH.
Biospecimens
TissueLungPreservation Types
FormalinDiagnoses
NeoplasticCarcinomaPlatforms
DNANext generation sequencingDNADNA sequencingDNAFISHDNAPCRPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Next generation sequencing Specific Technology platform ARMS-PCRFISHSanger sequencing